Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07128069 · ClinicalTrials.gov registry record · NA

Can Vitamin D Reduce the Burden of COVID-19?

A NA study of COVID-19, sponsored by University of Chicago.

Completed
Registry status
NA
Development phase
2,093
Enrollment target
1
Study location

NCT07128069: Completed NA study of COVID-19, sponsored by University of Chicago.

NCT07128069 is a NA study of COVID-19 that has completed, run by University of Chicago. The registered enrollment target is 2,093 participants, below the 38,458-participant average among 298 other COVID-19 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07128069, a NA study of COVID-19, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
NA
Development phase
2,093 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the risks of COVID-19 in individuals from the Chicagoland area and other communities in the United States randomized to low (400 IU/day) versus moderate (4,000 IU/day) dose vitamin D.

Primary Outcome

Reported in a post-randomization survey

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Vitamin D 400IU
  • DIETARY_SUPPLEMENT Vitamin D 4000IU

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 2,093 participants
Start Date 2020-12-28
Est. Completion 2025-02-15
Phase NA
University of Chicago

796 total trials

What the finished NCT07128069 record still lists

NCT07128069 is an interventional study that assigns participants to a tested intervention. Its 2,093 participants enrollment target places it among the larger protocols in the corpus, below the 38,458-participant average among 298 other COVID-19 trials with a reported enrollment target (95% lower).

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Vitamin D 400IU is the first listed.

NCT07128069 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07128069 about?

NCT07128069 is a clinical study titled "Can Vitamin D Reduce the Burden of COVID-19?". The purpose of this study is to compare the risks of COVID-19 in individuals from the Chicagoland area and other communities in the United States randomized to low (400 IU/day) versus moderate (4,000 IU/day) dose vitamin D.

What is the current status of trial NCT07128069?

This trial is currently completed. It is a NA study. The enrollment target is 2,093 participants. The study started on 2020-12-28. Estimated completion is 2025-02-15.

What conditions does trial NCT07128069 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT07128069?

The interventions under investigation include: Vitamin D 400IU (DIETARY_SUPPLEMENT), Vitamin D 4000IU (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07128069?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07128069 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07128069's enrollment target sits among peer trials

2,093 42nd of 298 higher than 257 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04649242 · 2,100 participants · Phase 3

    Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  • NCT05206331 · 2,100 participants · Phase 4

    CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

  • NCT05270499 · 2,100 participants

    Aveir VR Real-World Evidence Post-Approval Study

  • NCT06324981 · 2,100 participants · NA

    Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07128069, the US trial registry maintained by the National Library of Medicine. NCT07128069 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.